Comment
Author: Admin | 2025-04-28
Include:imatinib (Gleevec)dasatinib (Sprycel)nilotinib (Tasigna)Talk with your doctor if you’re interested in trying a different drug to treat Ph+ CML.You may wonder how Bosulif compares to other medications that are prescribed for similar uses. Here we look at how Bosulif and Gleevec are alike and different.IngredientsBosulif contains the drug bosutinib. Gleevec contains the drug imatinib.UsesThe Food and Drug Administration (FDA) has approved both Bosulif and Gleevec to treat certain types of blood cancers.Both Bosulif and Gleevec are FDA-approved to treat:newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in adults*Ph+ CML in adults who’ve tried a previous treatment that either didn’t work or caused negative side effects that required stopping treatmentIn addition, Gleevec is FDA-approved to treat Ph+ CML in children. (Bosulif is only approved for use in adults.)Gleevec is also approved to treat these other types of cancer:Ph+ acute lymphocyte leukemia (ALL)bone marrow cancers, such as myelodysplastic syndrome and myeloproliferative diseasehypereosinophilic syndrome or chronic eosinophilic leukemia (a group of blood disorders characterized by high numbers of a blood cell called eosinophils)mastocytosis (a condition in which cells called mast cells build up in the skin and internal organs)certain types of skin cancerKit-positive gastrointestinal (stomach) cancer* For this use, Bosulif received accelerated approval from the FDA, while Gleevec has full FDA approval. (Accelerated approval is based on early clinical trial data. A decision for full approval will be made after a longer ongoing clinical trial is completed.)Drug forms and administrationBoth Bosulif and Gleevec come as a tablet you take by mouth. Bosulif
Add Comment